{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:30:38Z","timestamp":1768005038370,"version":"3.49.0"},"publisher-location":"New York, NY","reference-count":69,"publisher":"Springer US","isbn-type":[{"value":"9781071614495","type":"print"},{"value":"9781071614501","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-1450-1_2","type":"book-chapter","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T20:09:06Z","timestamp":1630699746000},"page":"27-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Autoimmune Diseases with Therapeutic Antibodies: Lessons Learned from PID Patients Allow for Stratification of the Infection Risk"],"prefix":"10.1007","author":[{"given":"Joyce J. B. C.","family":"van Beers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan G. M. C.","family":"Damoiseaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"key":"2_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/jir.2011.0065","volume":"31","author":"KD Moudgil","year":"2011","unstructured":"Moudgil KD, Choubey D (2011) Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interf Cytokine Res 31:695\u2013703","journal-title":"J Interf Cytokine Res"},{"key":"2_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/187152809787582543","volume":"8","author":"A Mootoo","year":"2009","unstructured":"Mootoo A, Stylianou E, Arias MA et al (2009) Tnf-alpha in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets 8:53\u201362","journal-title":"Inflamm Allergy Drug Targets"},{"key":"2_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","volume":"10","author":"H Wajant","year":"2003","unstructured":"Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45\u201365","journal-title":"Cell Death Differ"},{"key":"2_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1124\/pr.114.009639","volume":"67","author":"S Siebert","year":"2015","unstructured":"Siebert S, Tsoukas A, Robertson J et al (2015) Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev 67:280\u2013309","journal-title":"Pharmacol Rev"},{"key":"2_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12026-014-8565-5","volume":"60","author":"C Selmi","year":"2014","unstructured":"Selmi C, Generali E, Massarotti M et al (2014) New treatments for inflammatory rheumatic disease. Immunol Res 60:277\u2013288","journal-title":"Immunol Res"},{"key":"2_CR6","doi-asserted-by":"publisher","first-page":"vii5","DOI":"10.1093\/rheumatology\/key059","volume":"57","author":"R Caporali","year":"2018","unstructured":"Caporali R, Crepaldi G, Codullo V et al (2018) 20 years of experience with tumour necrosis factor inhibitors: What have we learned? Rheumatology 57:vii5\u2013vii10","journal-title":"Rheumatology"},{"key":"2_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","volume":"8","author":"RS Wallis","year":"2008","unstructured":"Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8:601\u2013611","journal-title":"Lancet Infect Dis"},{"key":"2_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/jpet.301.2.418","volume":"301","author":"B Scallon","year":"2002","unstructured":"Scallon B, Cai A, Solowski N et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418\u2013426","journal-title":"J Pharmacol Exp Ther"},{"key":"2_CR9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1006\/cyto.1995.0091","volume":"7","author":"BJ Scallon","year":"1995","unstructured":"Scallon BJ, Trinh H, Nedelman M et al (1995) Functional comparisons of different tumour necrosis factor receptor\/igg fusion proteins. Cytokine 7:759\u2013770","journal-title":"Cytokine"},{"key":"2_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187572","volume":"12","author":"A Arakelyan","year":"2017","unstructured":"Arakelyan A, Nersisyan L, Poghosyan D et al (2017) Autoimmunity and autoinflammation: a systems view on signaling pathway dysregulation profiles. PLoS One 12:e0187572","journal-title":"PLoS One"},{"key":"2_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1086\/375587","volume":"37","author":"I Caragol","year":"2003","unstructured":"Caragol I, Raspall M, Fieschi C et al (2003) Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor beta1 deficiency. Clin Infect Dis 37:302\u2013306","journal-title":"Clin Infect Dis"},{"key":"2_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.smim.2014.09.008","volume":"26","author":"J Bustamante","year":"2014","unstructured":"Bustamante J, Boisson-Dupuis S, Abel L et al (2014) Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of ifn-gamma immunity. Semin Immunol 26:454\u2013470","journal-title":"Semin Immunol"},{"key":"2_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/rheumatology\/kex186","volume":"57","author":"A Schurich","year":"2018","unstructured":"Schurich A, Raine C, Morris V et al (2018) The role of il-12\/23 in t cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade. Rheumatology (Oxford) 57:246\u2013254","journal-title":"Rheumatology (Oxford)"},{"key":"2_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.smim.2006.07.010","volume":"18","author":"O Filipe-Santos","year":"2006","unstructured":"Filipe-Santos O, Bustamante J, Chapgier A et al (2006) Inborn errors of il-12\/23- and ifn-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 18:347\u2013361","journal-title":"Semin Immunol"},{"key":"2_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04146.x","volume":"161","author":"J Harris","year":"2010","unstructured":"Harris J, Keane J (2010) How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 161:1\u20139","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2_CR16","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s10067-019-04866-x","volume":"39","author":"NS Sartori","year":"2020","unstructured":"Sartori NS, de Andrade NPB, da Silva Chakr RM (2020) Incidence of tuberculosis in patients receiving anti-tnf therapy for rheumatic diseases: a systematic review. Clin Rheumatol 39(5):1439\u20131447","journal-title":"Clin Rheumatol"},{"key":"2_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224963","volume":"14","author":"NS Sartori","year":"2019","unstructured":"Sartori NS, Picon P, Papke A et al (2019) A population-based study of tuberculosis incidence among rheumatic disease patients under anti-tnf treatment. PLoS One 14:e0224963","journal-title":"PLoS One"},{"key":"2_CR18","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR et al (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122\u20132127","journal-title":"Arthritis Rheum"},{"key":"2_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00109-016-1391-6","volume":"94","author":"M Perusina Lanfranca","year":"2016","unstructured":"Perusina Lanfranca M, Lin Y, Fang J et al (2016) Biological and pathological activities of interleukin-22. J Mol Med (Berl) 94:523\u2013534","journal-title":"J Mol Med (Berl)"},{"key":"2_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957\u2013970","journal-title":"N Engl J Med"},{"key":"2_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/14740338.2020.1703946","volume":"19","author":"A Zabotti","year":"2020","unstructured":"Zabotti A, Goletti D, Lubrano E et al (2020) The impact of the interleukin 12\/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf 19:69\u201382","journal-title":"Expert Opin Drug Saf"},{"key":"2_CR22","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.4049\/jimmunol.171.10.5165","volume":"171","author":"JM Curtsinger","year":"2003","unstructured":"Curtsinger JM, Johnson CM, Mescher MF (2003) Cd8 t cell clonal expansion and development of effector function require prolonged exposure to antigen, costimulation, and signal 3 cytokine. J Immunol 171:5165\u20135171","journal-title":"J Immunol"},{"key":"2_CR23","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/eji.201242598","volume":"42","author":"AL Croxford","year":"2012","unstructured":"Croxford AL, Mair F, Becher B (2012) Il-23: one cytokine in control of autoimmunity. Eur J Immunol 42:2263\u20132273","journal-title":"Eur J Immunol"},{"key":"2_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.71","volume":"5","author":"S Okada","year":"2016","unstructured":"Okada S, Puel A, Casanova JL et al (2016) Chronic mucocutaneous candidiasis disease associated with inborn errors of il-17 immunity. Clin Transl Immunol 5:e114","journal-title":"Clin Transl Immunol"},{"key":"2_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/ACI.0b013e328358cc0b","volume":"12","author":"A Puel","year":"2012","unstructured":"Puel A, Cypowyj S, Marodi L et al (2012) Inborn errors of human il-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 12:616\u2013622","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"2_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","volume":"79","author":"X Li","year":"2020","unstructured":"Li X, Andersen KM, Chang HY et al (2020) Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis 79(2):285\u2013291","journal-title":"Ann Rheum Dis"},{"key":"2_CR27","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/jdv.12046","volume":"27","author":"AB Kimball","year":"2013","unstructured":"Kimball AB, Papp KA, Wasfi Y et al (2013) Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the phoenix 1 study. J Eur Acad Dermatol Venereol 27:1535\u20131545","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molimm.2012.11.006","volume":"55","author":"S Schmidt","year":"2013","unstructured":"Schmidt S, Moser M, Sperandio M (2013) The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol 55:49\u201358","journal-title":"Mol Immunol"},{"key":"2_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12026-009-8101-1","volume":"45","author":"YM Hyun","year":"2009","unstructured":"Hyun YM, Lefort CT, Kim M (2009) Leukocyte integrins and their ligand interactions. Immunol Res 45:195\u2013208","journal-title":"Immunol Res"},{"issue":"Pt 1","key":"2_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1242\/jcs.106.1.109","volume":"106","author":"MJ May","year":"1993","unstructured":"May MJ, Entwistle G, Humphries MJ et al (1993) Vcam-1 is a cs1 peptide-inhibitable adhesion molecule expressed by lymph node high endothelium. J Cell Sci 106(Pt 1):109\u2013119","journal-title":"J Cell Sci"},{"key":"2_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/med.21601","volume":"40","author":"I Dotan","year":"2020","unstructured":"Dotan I, Allez M, Danese S et al (2020) The role of integrins in the pathogenesis of inflammatory bowel disease: approved and investigational anti-integrin therapies. Med Res Rev 40:245\u2013262","journal-title":"Med Res Rev"},{"key":"2_CR32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/13543776.2018.1549227","volume":"28","author":"H Li","year":"2018","unstructured":"Li H, Huang SY, Shi FH et al (2018) Alpha4beta7 integrin inhibitors: a patent review. Expert Opin Ther Pat 28:903\u2013917","journal-title":"Expert Opin Ther Pat"},{"key":"2_CR33","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","volume":"24","author":"SC Park","year":"2018","unstructured":"Park SC, Jeen YT (2018) Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 24:1868\u20131880","journal-title":"World J Gastroenterol"},{"key":"2_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/gut.2007.145698","volume":"57","author":"J Verbeeck","year":"2008","unstructured":"Verbeeck J, Van Assche G, Ryding J et al (2008) Jc viral loads in patients with crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 57:1393\u20131397","journal-title":"Gut"},{"key":"2_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.hoc.2012.10.001","volume":"27","author":"E van de Vijver","year":"2013","unstructured":"van de Vijver E, van den Berg TK, Kuijpers TW (2013) Leukocyte adhesion deficiencies. Hematol Oncol Clin North Am 27:101\u2013116","journal-title":"Hematol Oncol Clin North Am"},{"key":"2_CR36","first-page":"16","volume":"20","author":"ES Harris","year":"2013","unstructured":"Harris ES, Weyrich AS, Zimmerman GA (2013) Lessons from rare maladies: leukocyte adhesion deficiency syndromes. Curr Opin Hematol 20:16\u201325","journal-title":"Curr Opin Hematol"},{"key":"2_CR37","first-page":"39","volume":"1","author":"A Fischer","year":"1988","unstructured":"Fischer A, Lisowska-Grospierre B, Anderson DC et al (1988) Leukocyte adhesion deficiency: molecular basis and functional consequences. Immunodefic Rev 1:39\u201354","journal-title":"Immunodefic Rev"},{"key":"2_CR38","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1182\/blood-2011-02-337188","volume":"119","author":"E van de Vijver","year":"2012","unstructured":"van de Vijver E, De Cuyper IM, Gerrits AJ et al (2012) Defects in glanzmann thrombasthenia and lad-iii (lad-1\/v) syndrome: the role of integrin beta1 and beta3 in platelet adhesion to collagen. Blood 119:583\u2013586","journal-title":"Blood"},{"key":"2_CR39","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1172\/JCI118361","volume":"96","author":"ML Phillips","year":"1995","unstructured":"Phillips ML, Schwartz BR, Etzioni A et al (1995) Neutrophil adhesion in leukocyte adhesion deficiency syndrome type 2. J Clin Invest 96:2898\u20132906","journal-title":"J Clin Invest"},{"key":"2_CR40","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058\u20131066","journal-title":"N Engl J Med"},{"key":"2_CR41","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ (2001) Complement. Second of two parts. N Engl J Med 344:1140\u20131144","journal-title":"N Engl J Med"},{"key":"2_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4614-4118-2_10","volume":"735","author":"AM Risitano","year":"2013","unstructured":"Risitano AM (2013) Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol 735:155\u2013172","journal-title":"Adv Exp Med Biol"},{"key":"2_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00281-017-0663-8","volume":"40","author":"EKS Wong","year":"2018","unstructured":"Wong EKS, Kavanagh D (2018) Diseases of complement dysregulation-an overview. Semin Immunopathol 40:49\u201364","journal-title":"Semin Immunopathol"},{"key":"2_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.trsl.2014.10.010","volume":"165","author":"EK Wong","year":"2015","unstructured":"Wong EK, Kavanagh D (2015) Anticomplement c5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 165:306\u2013320","journal-title":"Transl Res"},{"key":"2_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","volume":"31","author":"AC Baines","year":"2017","unstructured":"Baines AC, Brodsky RA (2017) Complementopathies. Blood Rev 31:213\u2013223","journal-title":"Blood Rev"},{"key":"2_CR46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1128\/CMR.4.3.359","volume":"4","author":"JE Figueroa","year":"1991","unstructured":"Figueroa JE, Densen P (1991) Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4:359\u2013395","journal-title":"Clin Microbiol Rev"},{"key":"2_CR47","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.4049\/jimmunol.175.9.5912","volume":"175","author":"MC van Zelm","year":"2005","unstructured":"van Zelm MC, van der Burg M, de Ridder D et al (2005) Ig gene rearrangement steps are initiated in early human precursor b cell subsets and correlate with specific transcription factor expression. J Immunol 175:5912\u20135922","journal-title":"J Immunol"},{"key":"2_CR48","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nri844","volume":"2","author":"F Mackay","year":"2002","unstructured":"Mackay F, Browning JL (2002) Baff: a fundamental survival factor for B cells. Nat Rev Immunol 2:465\u2013475","journal-title":"Nat Rev Immunol"},{"key":"2_CR49","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.4049\/jimmunol.159.7.3278","volume":"159","author":"S Sato","year":"1997","unstructured":"Sato S, Miller AS, Howard MC et al (1997) Regulation of b lymphocyte development and activation by the cd19\/cd21\/cd81\/leu 13 complex requires the cytoplasmic domain of cd19. J Immunol 159:3278\u20133287","journal-title":"J Immunol"},{"key":"2_CR50","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta R, Benson MJ, de Vries VC et al (2009) Molecular mechanism and function of cd40\/cd40l engagement in the immune system. Immunol Rev 229:152\u2013172","journal-title":"Immunol Rev"},{"key":"2_CR51","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","volume":"8","author":"RJ Ludwig","year":"2017","unstructured":"Ludwig RJ, Vanhoorelbeke K, Leypoldt F et al (2017) Mechanisms of autoantibody-induced pathology. Front Immunol 8:603","journal-title":"Front Immunol"},{"key":"2_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","volume":"9","author":"HM Gurcan","year":"2009","unstructured":"Gurcan HM, Keskin DB, Stern JN et al (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9:10\u201325","journal-title":"Int Immunopharmacol"},{"key":"2_CR53","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5114\/aoms.2016.60338","volume":"13","author":"M Pac","year":"2017","unstructured":"Pac M, Bernatowska EA, Kierkus J et al (2017) Gastrointestinal disorders next to respiratory infections as leading symptoms of x-linked agammaglobulinemia in children - 34-year experience of a single center. Arch Med Sci 13:412\u2013417","journal-title":"Arch Med Sci"},{"key":"2_CR54","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.waojou.2019.100018","volume":"12","author":"ZA El-Sayed","year":"2019","unstructured":"El-Sayed ZA, Abramova I, Aldave JC et al (2019) X-linked agammaglobulinemia (xla):phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J 12:100018","journal-title":"World Allergy Organ J"},{"key":"2_CR55","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase iii trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"2_CR56","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","volume":"47","author":"JC Gea-Banacloche","year":"2010","unstructured":"Gea-Banacloche JC (2010) Rituximab-associated infections. Semin Hematol 47:187\u2013198","journal-title":"Semin Hematol"},{"key":"2_CR57","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.3389\/fimmu.2018.02698","volume":"9","author":"C Kowalczyk-Quintas","year":"2018","unstructured":"Kowalczyk-Quintas C, Chevalley D, Willen L et al (2018) Inhibition of membrane-bound baff by the anti-baff antibody belimumab. Front Immunol 9:2698","journal-title":"Front Immunol"},{"key":"2_CR58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","volume":"36","author":"S Nakayamada","year":"2016","unstructured":"Nakayamada S, Tanaka Y (2016) Baff- and april-targeted therapy in systemic autoimmune diseases. Inflamm Regen 36:6","journal-title":"Inflamm Regen"},{"key":"2_CR59","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12728","volume":"287","author":"C Cunningham-Rundles","year":"2019","unstructured":"Cunningham-Rundles C (2019) Common variable immune deficiency: dissection of the variable. Immunol Rev 287:145\u2013161","journal-title":"Immunol Rev"},{"key":"2_CR60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nri1781","volume":"6","author":"Y Takahama","year":"2006","unstructured":"Takahama Y (2006) Journey through the thymus: stromal guides for t-cell development and selection. Nat Rev Immunol 6:127\u2013135","journal-title":"Nat Rev Immunol"},{"key":"2_CR61","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1084\/jem.20042524","volume":"201","author":"WA Dik","year":"2005","unstructured":"Dik WA, Pike-Overzet K, Weerkamp F et al (2005) New insights on human t cell development by quantitative t cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 201:1715\u20131723","journal-title":"J Exp Med"},{"key":"2_CR62","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00011-017-1032-8","volume":"66","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Su H, Shen X et al (2017) The immunological function of cd52 and its targeting in organ transplantation. Inflamm Res 66:571\u2013578","journal-title":"Inflamm Res"},{"key":"2_CR63","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/cei.13208","volume":"194","author":"Z Li","year":"2018","unstructured":"Li Z, Richards S, Surks HK et al (2018) Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol 194:295\u2013314","journal-title":"Clin Exp Immunol"},{"key":"2_CR64","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1046\/j.1365-2249.2000.01359.x","volume":"122","author":"A Fischer","year":"2000","unstructured":"Fischer A (2000) Severe combined immunodeficiencies (scid). Clin Exp Immunol 122:143\u2013149","journal-title":"Clin Exp Immunol"},{"key":"2_CR65","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","volume":"78","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Fox E, Vladic A et al (2012) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of camms223 clinical trial. Neurology 78:1069\u20131078","journal-title":"Neurology"},{"key":"2_CR66","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1177\/1352458518796675","volume":"25","author":"S Wray","year":"2019","unstructured":"Wray S, Havrdova E, Snydman DR et al (2019) Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the camms223, care-ms i, and care-ms ii studies and the camms03409 extension study. Mult Scler 25:1605\u20131617","journal-title":"Mult Scler"},{"key":"2_CR67","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamaneurol.2016.0146","volume":"73","author":"H Penkert","year":"2016","unstructured":"Penkert H, Delbridge C, Wantia N et al (2016) Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol 73:757\u2013759","journal-title":"JAMA Neurol"},{"key":"2_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s13760-018-0882-3","volume":"118","author":"C Lambert","year":"2018","unstructured":"Lambert C, Dubois B, Dive D et al (2018) Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a belgian consensus. Acta Neurol Belg 118:7\u201311","journal-title":"Acta Neurol Belg"},{"key":"2_CR69","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1007\/s00415-018-8822-y","volume":"265","author":"V Devonshire","year":"2018","unstructured":"Devonshire V, Phillips R, Wass H et al (2018) Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol 265:2494\u20132505","journal-title":"J Neurol"}],"container-title":["Methods in Molecular Biology","Therapeutic Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1450-1_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T15:39:12Z","timestamp":1673192352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1450-1_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"ISBN":["9781071614495","9781071614501"],"references-count":69,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1450-1_2","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,4]]},"assertion":[{"value":"4 September 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}